Amyloid imaging as a surrogate marker in clinical trials in Alzheimer's disease

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 55, Issue 3, 2011, Pages 265-279

  Scheinin, Noora M ^a   Scheinin, Mika ^b   Rinne, J O ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Alzheimer's disease; Amyloid; Biomarkers; Positron emission tomography

Indexed keywords

AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

ALZHEIMER DISEASE; CLINICAL TRIAL (TOPIC); COGNITIVE DEFECT; EARLY DIAGNOSIS; HUMAN; IN VIVO STUDY; NEUROIMAGING; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; REVIEW;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANILINE COMPOUNDS; BIOLOGICAL MARKERS; BRAIN; CLINICAL TRIALS AS TOPIC; FLUORODEOXYGLUCOSE F18; HUMANS; MODELS, NEUROLOGICAL; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; THIAZOLES;

EID: 79960982332     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Carter MD, Simms GA, Weaver DF. The development of new therapeutics for Alzheimer's disease. Clin Pharmacol Ther 2010;88:475-86.
2. Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol 2010;9:702-16.
3. Lemere CA, Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol 2010;6:108-19.
4. Ligthart SA, Moll van Charante EP, Van Gool WA, Richard E. Treatment of cardiovascular risk factors to prevent cognitive decline and dementia: a systematic review. Vasc Health Risk Manag 2010;6:775-85.
5. Hardy J, Selkoe D. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6. (Pubitemid 34790756)
6. Hampel H, Frank R, Broich K, Teipel SJ, Katz RG, Hardy J et al. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives. Nat Rev Drug Discov 2010;9:560-74.
7. Mathis C, Lopresti B, Klunk W Impact of amyloid imaging on drug development in Alzheimer's disease. Nucl Med Biol 2007;34:809-22. (Pubitemid 47503823)
8. Friedland RP, Kalaria R, Berridge M, Miraldi F, Hedera P, Reno J et al. Neuroimaging of vessel amyloid in Alzheimer's disease. Ann N Y Acad Sci 1997;826:242-7. (Pubitemid 27478045)
9. Wadghiri YZ, Sigurdsson EM, Sadowski M, Elliott JI, Li Y, Scholtzova H et al. Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med 2003;50:293-302. (Pubitemid 36950848)
10. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurology 2004;3:519-27. (Pubitemid 39485859)
11. Styren S, Hamilton R, Styren G, Klunk W. X-34, a fluorescent derivative of Congo red: a novel histochemical stain for Alzheimer's disease pathology. J Histochem Cytochem 2000;48:1223-32.
12. Klunk WE, Bacskai BJ, Mathis CA, Kajdasz ST, McLellan ME, Frosch MP et al. Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative. J Neuropathol Exp Neurol 2002;61:797-805. (Pubitemid 35001352)
13. Klunk W, Wang Y, Huang G, Debnath M, Holt D, Mathis C. Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain. Life Sci 2001;69:1471-84. (Pubitemid 32786721)
14. Mathis CA, Bacskai BJ, Kajdasz ST, McLellan ME, Frosch MP, Hyman BT et al. A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain. Bioorg Med Chem Lett 2002;12:295-8. (Pubitemid 34113887)
15. Bacskai BJ, Hickey GA, Skoch J, Kajdasz ST, Wang Y, Huang GF et al. Four-dimensional multiphoton imaging of brain entry, amyloid binding, and clearance of an amyloid-beta ligand in transgenic mice. Proc Natl Acad Sci USA 2003;100:12462-7. (Pubitemid 37271582)
16. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740-54. (Pubitemid 36702542)
17. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19. (Pubitemid 38269583)
18. Johnson AE, Jeppsson F, Sandell J, Wensbo D, Neelissen JA, Juréus A et al. AZD2184: a radioligand for sensitive detection of beta-amyloid deposits. J Neurochem 2009;108:1177-86.
19. Juréus A, Swahn BM, Sandell J, Jeppsson F, Johnson AE, Johnström P et al. Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand. J Neurochem 2010;114:784-94.
20. 11C]SB-13 PET. Am J Geriatr Psychiatry 2004;12:584-95. (Pubitemid 41031060)
21. Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, Maruyama M et al. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 2007;48:553-61. (Pubitemid 47571409)
22. 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol 2008;7:129-35.
23. Shoghi-Jadid K, Small GW, Agdeppa ED, Kepe V, Ercoli LM, Siddarth P et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. Am J Geriatr Psychiatry 2002;10:24-35. (Pubitemid 34052900)
24. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ et al. PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 2006;355:2652-3.
25. Suemoto T, Okamura N, Shiomitsu T, Suzuki M, Shimadzu H, Akatsu H et al. In vivo labeling of amyloid with BF-108. Neurosci Res 2004;48:65-74.
26. 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease. J Nucl Med 2009;50:1251-9.
27. 18F-labeled biphenylalkyne as a positron emission tomography imaging agent for beta-amyloid plaques. Nucl Med Biol 2009;36:411-7.
28. 18F-AV-45 (florbetapir). J Nucl Med 2010;51:913-20.
29. Klunk W, Mathis C. The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation. Curr Opin Neurol 2008;21:683-7.
30. Bacskai B, Frosch M, Freeman S, Raymond SB, Augustinack JC, Johnson KA et al. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol 2007;64:431-4.
31. Ikonomovic MD, Klunk WE, Abrahamson EE, Mathis CA, Price JC, Tsopelas ND et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain 2008;131:1630-45.
32. Kantarci K, Yang C, Schneider JA, Senjem ML, Reyes DA, Lowe VJ et al. Ante mortem amyloid imaging and β-amyloid pathology in a case with dementia with Lewy bodies. Neurobiol Aging 2010 [Epub ahead of print].
33. Leinonen V, Alafuzoff I, Aalto S, Suotunen T, Savolainen S, Nagren K et al. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B. Arch Neurol 2008;65:1304-9.
34. Buckner RL, Snyder AZ, Shannon BJ, LaRossa G, Sachs R, Fotenos AF et al. Molecular, structural, and functional characterization of Alzheimer's disease: Evidence for a relationship between default activity, amyloid, and memory. J Neurosci 2005;25:7709-17.
35. Price JC, Klunk WE, Lopresti BJ, Lu X, Hoge JA, Ziolko SK et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. Journal of Cerebral Blood Flow and Metabolism 2005;25:1528-47. (Pubitemid 41541962)
36. Archer HA, Edison P, Brooks DJ, Barnes J, Frost C, Yeatman T et al. Amyloid load and cerebral atrophy in Alzheimer's disease: An C-11-PIB positron emission tomography study. Annals of Neurology 2006;60:145-7.
37. Engler H, Forsberg A, Almkvist O, Blomquist G, Larsson E, Savitcheva I et al. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease. Brain 2006;129:2856-66. (Pubitemid 44684508)
38. 11C]PIB uptake in Alzheimer disease. Neurology 2006;67:1575-80. (Pubitemid 44747926)
39. 18F]FDG PET study. Neurology 2007;68:501-8.
40. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G et al. Imaging beta-amyloid burden in aging and dementia. Neurology 2007;68:1718-25. (Pubitemid 46763260)
41. 11C]PIB uptake and brain volume in patients with Alzheimer disease and controls. Neurology 2009;73:1186-92.
42. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 2007;6:734-6.
43. 18F-FDG PET for detection of Alzheimer's disease. J Nucl Med 2007;48:547-52. (Pubitemid 47571408)
44. 11C]PIB PET in patients with cognitive impairment. Eur J Nucl Med Mol Imaging 2010;37:1141-7.
45. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS et al. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-65.
46. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-72.
47. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology 2007;68:1205-12.
48. 11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008;79:1331-8.
49. Engler H, Santillo AF, Wang SX, Lindau M, Savitcheva I, Nordberg A et al. In vivo amyloid imaging with PET in frontotemporal dementia. Eur J Nucl Med Mol Imaging 2008;35:100-6.
50. Gomperts SN, Rentz DM, Moran E, Becker JA, Locascio JJ, Klunk WE et al. Imaging amyloid deposition in Lewy body diseases. Neurology 2008;71:903-10.
51. 11C]PIB binding in Parkinson's disease dementia. Neuroimage 2008;39:1027-33.
52. Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C et al. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 2009;34:107-12.
53. 18F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia. Parkinsonism Relat Disord 2010;16:666-70.
54. Johnson KA, Gregas M, Becker JA, Kinnecom C, Salat DH, Moran EK et al. Imaging of amyloid burden and distribution in cerebral amyloid angiopathy. Ann Neurol 2007;62:229-34.
55. Ng S, Villemagne V, Masters C, Rowe C. Evaluating atypical dementia syndromes using positron emission tomography with carbon H labeled Pittsburgh Compound B. Arch Neurol 2007;64:1140-4. (Pubitemid 47258073)
56. 11C]PIB uptake shows predominantly striatal increase in variant Alzheimer's disease. Brain 2008;131:1845-53.
57. Remes AM, Laru L, Tuominen H, Aalto S, Kemppainen N, Motionen H et al. Carbon 11-labeled Pittsburgh compound B positron emission tomographic amyloid imaging in patients with APP locus duplication. Arch Neurol 2008;65:540-4.
58. 11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 2009;80:998-1001.
59. Pike KE, Savage G, Villemagne VL, Ng S, Moss SA, Maruff P et al. Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. Brain 2007;130:2837-44.
60. Grimmer T, Henriksen G, Wester HJ, Förstl H, Klunk WE, Mathis CA et al. Clinical severity of Alzheimer's disease is associated with PIB uptake in PET. Neurobiol Aging 2009;30:1902-9.
61. Rowe CC, Ellis KA, Rimajova M, Bourgeat P, Pike KE, Jones G et al. Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. Neurobiol Aging 2010;31:1275-83.
62. Lockhart A, Lamb JR, Osredkar T, Sue LI, Joyce JN, Ye L et al. PIB is a non-specific imaging marker of amyloid-beta (A beta) peptide-related cerebral amyloidosis. Brain 2007;130:2607-15. (Pubitemid 47511709)
63. Davies L, Wolska B, Hilbich C, Multhaup G, Martins R, Simms G et al. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 1988;38:1688-93. (Pubitemid 18265030)
64. 11C]PIB in a nondemented population: Implication for use as an antecedent marker of Alzheimer's disease. Neuropsychopharmacology 2005;30:S223-S3.
65. Villemagne VL, Pike KE, Darby D, Maruff P, Savage G, Ng S et al. Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia 2008;46:1688-97.
66. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W et al. Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A 2009;106:6820-5.
67. Reiman EM, Langbaum JB, Tariot PN. Alzheimer's prevention initiative: a proposal to evaluate presymptomatic treatments as quickly as possible. Biomark Med 2010;4:3-14.
68. 11C]PIB uptake is increased in mild cognitive impairment. Neurology 2007;68:1603-6.
69. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 2008;29:1456-5.
70. 11C-PIB PET study. Neurology 2009.
71. Okello A, Edison P, Archer HA, Turkheimer FE, Kennedy J, Bullock R et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009;72:56-62.
72. Wolk DA, Price JC, Saxton JA, Snitz BE, James JA, Lopez OL et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol 2009;65:557-68.
73. 11C]PIB uptake and cerebrospinal fluid beta-amyloid in mild cognitive impairment. Dement Geriatr Cogn Disord 2008;26:378-83.
74. Jack CR Jr, Lowe VJ, Weigand SD, Wiste HJ, Senjem ML, Knopman DS et al. Alzheimer's Disease Neuroimaging Initiative. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 2009;132:1355-65.
75. Koivunen J, Scheinin N, Aalto S, Vahlberg T, Någren K, Helin S et al. PET imaging of amyloid deposition in patients with mild cognitive impairment: A two year follow-up study. Neurology 2011 Feb 16 [Epub ahead of print].
76. Chételat G, Villemagne VL, Bourgeat P, Pike KE, Jones G, Ames D et al. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease. Ann Neurol 2010;67:317-24.
77. Aizenstein HJ, Nebes RD, Saxton JA, Price JC, Mathis CA, Tsopelas ND et al. Frequent amyloid deposition without significant cognitive impairment among the elderly. Arch Neurol 2008;65:1509-17.
78. 11C-PiB and structural MRI provide complementary information in imaging of Alzheimers disease and amnestic mild cognitive impairment. Brain 2008;131:665-80. (Pubitemid 351294719)
79. 11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-52. (Pubitemid 44214969)
80. Mormino EC, Kluth JT, Madison CM, Rabinovici GD, Baker SL, Miller BL et al. Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain 2009;132:1310-23.
81. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007;27:6174-84. (Pubitemid 46890033)
82. Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M et al. Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 1999;65:664-70. (Pubitemid 30468710)
83. Bertram L, Tanzi R. The current status of Alzheimer's disease genetics: what do we tell the patients? Pharmacol Res 2004;50:385-96.
84. Parsey RV, Sokol LO, Bélanger MJ, Kumar JS, Simpson NR, Wang T et al. Amyloid plaque imaging agent [C-11]-6-OH-BTA-1: biodistribution and radiation dosimetry in baboon. Nucl Med Commun 2005;26:875-80.
85. 11C-PIB in humans. J Nucl Med 2007;48:128-33.
86. 18F-BAY94-9172. J Nucl Med 2009;50:309-15.
87. IRCP. Addendum 6 to ICRP Publication 53: radiation doses of radiopharmaceuticals [Internet]. [cited 2011 February 18]. Available at: www.icrp.orc/docs/Add-5-7-to-P53pdf, 2002.
88. Joachim C, Morris J, Selkoe D. Diffuse senile plaques occur commonly in the cerebellum in Alzheimer's disease. Am J Pathol 1989;135:309-19.
89. Lopresti BJ, Klunk WE, Mathis CA, Hoge JA, Ziolko SK, Lu X et al. Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: A comparative analysis. J Nucl Med 2005;46:1959-72.
90. 11C]PIB uptake using 30-min scanning data. Eur J Nucl Med Mol Imaging 2009;36:1651-60.
91. Ziolko SK, Weissfeld LA, Klunk WE, Mathis CA, Hoge JA, Lopresti BJ et al. Evaluation of voxel-based methods for the statistical analysis of PIB PET amyloid imaging studies in Alzheimer's disease. Neuroimage 2006;33:94-102.
92. 11C-PIB scans for diagnosing Alzheimer's disease. J Nucl Med 2008;49:1262-9.
93. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 2002;416:535-9.
94. Hyman BT, Marzloff K, Arriagada PV. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J Neuropathol Exp Neurol 1993;52:594-600.
95. Kadir A, Andreasen N, Almkvist O, Wall A, Forsberg A, Engler H et al. Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease. Ann Neurol 2008;63:621-31.
96. Klein J. Phenserine. Expert Opin Investig Drugs 2007;16:1087-97.
97. Winblad B, Giacobini E, Frölich L, Friedhoff LT, Bruinsma G, Becker RE et al. Phenserine efficacy in Alzheimer's disease. J Alzheimers Dis 2010;22:1201-8.
98. Liang KY, Mintun MA, Fagan AM, Goate AM, Bugg JM, Holtzman DM et al. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. Ann Neurol 2010;68:311-8.
99. Nordberg A. Amyloid imaging in early detection of Alzheimer's disease. Neurodegener Dis 2010;7:136-8.